---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-223282"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2024-09-23T23:59:59+00:00"
generated_at: "2026-05-31T02:32:02.368546+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BioAtla licenses Nectin-4 x CD3 bispecific antibody to Context Therapeutics for up to $133.5M

## Summary
- BioAtla grants exclusive worldwide license to Context for two antibodies including BA3362 (CT-202), a Nectin-4 x CD3 TCE bispecific.
- BioAtla eligible for up to $133.5M total, including $15M upfront/near-term milestones and $118.5M in future milestones plus tiered royalties.
- BioAtla enters Global Transaction Agreement with Himalaya Therapeutics, consenting to license and sharing a mid-teens percentage of upfront/milestone payments.
- Context may terminate at will; BioAtla may terminate if Context halts development for 8 consecutive quarters.
- BioAtla agrees to refrain from competitive activities regarding Nectin-4 bispecific/multi-specific antibodies.

## SEC filing metadata
- accession: 0001193125-24-223282
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2024-09-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000119312524223282/0001193125-24-223282-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000119312524223282/d845616d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-223282
- JSON: https://secwatch.observer/filing/0001193125-24-223282.json
- Plain text: https://secwatch.observer/filing/0001193125-24-223282.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.